mRNA splice variant of the doublecortin-like kinase gene and its use in cancer diagnosis and therapy
View Patent ↗The present invention relates to novel nucleic acid and protein molecules and their use in neuroblastoma therapy and diagnosis.
1. A composition suitable for the treatment of neuroblastoma comprising a pharmaceutically and/or physiologically acceptable carrier and at least one antisense RNA or DNA oligonucleotide comprising one or more sequences selected from the group consisting of SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 19, and SEQ ID NO: 20.
2. The composition according to claim 1 , further comprising one or more targeting compounds, wherein said targeting compounds are capable of targeting neuroblastoma cells in vivo or in vitro.
3. The composition according to claim 2 , wherein the targeting compound is an immunoliposome or a monoclonal antibody.
4. The composition according to claim 1 , wherein said at least one antisense RNA oligonucleotide comprises 2′-O-methyl RNA or 2′-O-allyl RNA.
5. The composition according to claim 1 , wherein said at least one antisense RNA or DNA oligonucleotide comprises Peptide Nucleic Acids.
6. The composition according to claim 1 , wherein said at least one antisense RNA or DNA oligonucleotide comprises Locked Nucleic Acids.
7. The composition according to claim 1 , wherein the amount of said at least one antisense RNA or DNA oligonucleotide is between 0.05 and 5.0 μmol/ml.
8. A composition comprising a pharmaceutically and/or physiologically acceptable carrier and a nucleic acid sequence comprising SEQ ID NO: 2, or a complement thereof.
9. A composition suitable for the treatment of neuroblastoma comprising at least one antisense RNA or DNA oligonucleotide of 17-23 nucleotides comprising one or more sequences selected from the group consisting of SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 18, SEQ ID NO: 19, SEQ ID NO: 20, and sequences derived thereof in which 1, 2 or 3 nucleotides has been added, replaced or deleted.
10. The composition according to claim 9 , further comprising a pharmaceutically and/or physiologically acceptable carrier.
11. The composition according to claim 9 , wherein at least one antisense RNA or DNA oligonucleotide comprises Peptide Nucleic Acids.
12. The composition according to claim 9 , wherein at least one antisense RNA or DNA oligonucleotide comprises Locked Nucleic Acids.
13. The composition according to claim 9 , further comprising a targeting compound, which is capable of targeting neuroblastoma cells in vivo or in vitro.
14. The composition according to claim 13 , wherein the targeting compound is an immunoliposome or a monoclonal antibody.
15. The composition according to claim 9 , wherein said RNA oligonucleotide comprises 2′-O-methyl RNA or 2′-O-allyl RNA.
16. The composition according to claim 9 , wherein the amount of said at least one antisense RNA or DNA oligonucleotide is between 0.05 and 5.0 μmol/ml.